Castle Biosciences expects 2024 revenue at least $330M (≥50% growth); Medicare non-covers DecisionDx-SCC

CASTLE BIOSCIENCES INC

2024-FY EPS reported $0.62 revenue$332,069,000

Full-year 2024 revenue expected to meet or exceed top of guidance range $320-330M, at least 50% growth over 2023.
Delivered 96,071 total test reports in 2024, up 36% YoY; TissueCypher Barrett's Esophagus test grew 130%.
Year-end 2024 cash, cash equivalents and marketable securities approximately $293M.
Medicare contractor Novitas finalized non-coverage for DecisionDx-SCC test on January 9, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.